DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

786 Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine
with atenolol, amlodipine, or diltiazem on exercise tolerance
and angina frequency in patients with severe chronic angina:
A randomized, controlled trial. JAMA, 2004, 291:309–316.
Champagne CM. Dietary interventions on blood pressure: The
Dietary Approaches to Stop Hypertension (DASH) trials. Nutr
Rev, 2006, 64:S53–S56.
Charchar FJ, Zimmer LU, Tomaszewski M. The pressure of finding
human hypertension genes: New tools, old dilemmas.
J Hum Hypertens, 2008, 22:821–828.
Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert
consensus document: Use of sildenafil (VIAGRA) in patients
with cardiovascular disease. American College of Cardiology/
American Heart Association. J Am Coll Cardiol, 1999, 33:
273–282.
Chen Z, Zhang J, Stamler JS. Identification of the enzymatic
mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci
USA, 2002, 99:8306–8311.
Chi L, Uprichard AC, Lucchesi BR. Profibrillatory actions of
pinacidil in a conscious canine model of sudden coronary
death. J Cardiovasc Pharmacol, 1990, 15:452–464.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the
Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. Hypertension, 2003,
42:1206–1252.
Curtis MJ, Hearse DJ. Ischaemia-induced and reperfusioninduced
arrhythmias differ in their sensitivity to potassium:
Implications for mechanisms of initiation and maintenance of
ventricular fibrillation. J Mol Cell Cardiol, 1989, 21:21–40.
Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality
in the Swedish Trial in Old Patients with Hypertension
(STOP-Hypertension). Lancet, 1991, 338:1281–1285.
Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators.
Prevention of cardiovascular events with an antihypertensive regimen
of amlodipine adding perindopril as required versus
atenolol adding bendroflumethiazide as required, in the Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering
Arm (ASCOT-BPLA): A multicentre randomised controlled
trial. Lancet, 2005, 366:895–906.
Deedwania PC, Carbajal EV. Role of beta blockade in the treatment
of myocardial ischemia. Am J Cardiol, 1997, 80:23J–28J.
Dudzinski D, Igarashi J, Greif D, Michel T. The regulation and
pharmacology of endothelial nitric oxide synthase. Annu Rev
Pharmacol Toxicol, 2006, 46:235–276.
Egstrup K, Andersen PE Jr. Transient myocardial ischemia during
nifedipine therapy in stable angina pectoris, and its relation
to coronary collateral flow and comparison with metoprolol.
Am J Cardiol, 1993, 71:177–183.
Ellershaw DC, Gurney AM. Mechanisms of hyralazine induced
vasodilation in rabbit aorta and pulmonary artery. Br J
Pharmacol, 2001, 134:621–631.
Ellison DH, Loffing J. Thiazide effects and adverse effects:
Insights from molecular genetics. Hypertension, 2009, 54:
196–202.
Epstein BJ, Roberts ME. Managing peripheral edema in patients
with arterial hypertension. Am J Ther, 2009, 16:543–553.
Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive
effects of hydrochlorothiazide and chlorthalidone on
ambulatory and office blood pressure. Hypertension, 2006,
47:352–358.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Feelisch M. The use of nitric oxide donors in pharmacological
studies. Naunyn Schmiedebergs Arch Pharmacol, 1998, 358:
113–122.
Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic
Burden European Trial (TIBET): Effects of atenolol, nifedipine
SR and their combination on the exercise test and the total
ischaemic burden in 608 patients with stable angina. The
TIBET Study Group. Eur Heart J, 1996, 17:96–103.
Frampton JE, Curran MP. Aliskiren: A review of its use in the
management of hypertension. Drugs, 2007, 67:1767–1792.
Franker TD Jr, Fihn SD, Gibbons RJ, et al. 2007 chronic angina
focused update of the ACC/AHA 2002 guidelines for the management
of patients with chronic stable angina. Circulation,
2007, 116:2762–2772.
Franklin SS. Is there a preferred antihypertensive therapy for isolated
systolic hypertension and reduced arterial compliance?
Curr Hypertens Rep, 2000, 2:253–259.
Fung H-L. Biochemical mechanism of nitroglycerin action and
tolerance: Is this old mystery solved? Annu Rev Pharmacol
Toxicol, 2004, 44:67–85.
Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related
increase in mortality in patients with coronary heart disease.
Circulation, 1995, 92:1326–1331.
Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002
guideline update for the management of patients with chronic
stable angina—Summary article: A report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on the Management of
Patients with Chronic Stable Angina). Circulation, 2003,
107:149–158.
Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium
entry blockade. Pharmacol Rev, 1986, 38:321–416.
Godfraind T, Salomone S, Dessy C, et al. Selectivity scale of calcium
antagonists in the human cardiovascular system based on
in vitro studies. J Cardiovasc Pharmacol, 1992, 20(suppl 5):
S34–S41.
Goldstein DS, Levinson PD, Zimlichman R, et al. Clonidine suppression
testing in essential hypertension. Ann Intern Med,
1985, 102:42–49.
Gustafsson ÅB, Brunton LL. Attenuation of cyclic AMP accumulation
in adult rat cardiac fibroblasts by IL-1β and nitric
oxide: Role of cGMP-stimulated phosphodiesterase (PDE2).
Am J Physiol Cell, 2002, 283:C463–C471.
Hasenfuss G, Maier LS. Mechanisms of action of the new antiischemia
drug ranolazine. Clin Res Cardiol, 2008,
97:222–226.
Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis
of trials comparing beta-blockers, calcium antagonists, and
nitrates for stable angina. JAMA, 1999, 281:1927–1936.
Herrmann HC, Chang G, Klugherz BD, Mahoney PD.
Hemodynamic effects of sildenafil in men with severe coronary
artery disease. N Engl J Med, 2000, 342:1622–1626.
Hiatt WR. Medical treatment of peripheral arterial disease and
claudication. N Engl J Med, 2001, 344:1608–1621.
Hillis DL, Lange RA. Optimal management of acute coronary
syndromes. N Engl J Med, 2009, 360:2237–2258.
Hirsh AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice
guidelines for the management of patients with peripheral arterial
disease (lower extremity, renal, mesenteric, and abdominal
aortic). Circulation, 2006, 113:1474–1547.